Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan

PURPOSE: In patients with advanced colorectal cancer, FOLFIRI is considered as one of the reference first-line treatments. However, only about half of treated patients respond to this bi-therapy, and there is no clinically useful marker that predicts response. A major clinical challenge is to identi...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Del Rio, Maguy, Molina, Franck, Bascoul-Mollevi, Caroline, Copois, Virginie, Bibeau, Frédéric, Chalbos, Patrick, Bareil, Corinne, Kramar, Andrew, Salvetat, Nicolas, Fraslon, Caroline, Conseiller, Emmanuel, Granci, Virginie, Leblanc, Benjamin, Pau, Bernard, Martineau, Pierre, Ychou, Marc
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2007
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2257989/
https://ncbi.nlm.nih.gov/pubmed/17327601
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2006.07.4187
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items